AI interpretation based on checked source excerpts. Issuer assertions and evidence limitations remain explicit.
Policy quality-scores-2: six equally weighted categories. The overall score requires full coverage. Missing inputs are not zero. Qualitative grades are sourced interpretations, not probabilities. 5/6 · 18/10/2026
Moat50
Equal-weight average of four evidence-backed rubric grades (0–4), scaled to 100.
structural advantage · 3/4 · Granted patents, exclusive marketing rights and proprietary vaccine inputs establish meaningful replication barriers. Completed approvals and commercialization demonstrate their practical relevance, although protection covers only parts of the portfolio.
durability · 2/4 · Continuing approvals and proprietary know-how support renewal, but patents expire and protection varies by country. Realized generic erosion and dependence on licensed rights limit demonstrated durability.
customer dependency · 1/4 · Observed generic substitution and price sensitivity indicate fragile dependence on particular Zoetis products. Management's brand-loyalty belief does not establish strong switching friction; this assessment uses indirect demand evidence rather than customer-level retention data.
erosion resilience · 2/4 · International demand growth and new launches provide a demonstrated offset to erosion, but competition is already impairing major U.S. franchises and earnings. Resilience is mixed, with International growth partly assisted by reporting alignment changes.
Pricing power—
Insufficient evidence for every rubric criterion; no category score is inferred.
realized pricing · 2/4 · Poultry sales and consolidated cost-of-sales commentary demonstrate realized price benefits. Historical forced cuts and discounts against generics, together with current price sensitivity, establish uneven pricing power rather than broad immunity to competition.
retention · 2/4 · Indirect operating evidence shows continuing demand for International parasiticides, vaccines and diagnostics alongside declining dermatology and generic-exposed products. This supports mixed repeat-demand resilience, not a quantified retention rate.
margin resilience · 2/4 · Price increases and favorable manufacturing costs partly offset unfavorable mix and foreign exchange, but first-half cost of sales rose from 27.4% to 27.8% of revenue and U.S. earnings declined. This demonstrates partial resilience without inferring a moat from margin levels.
contractual freedom · — · Observed price changes establish pricing outcomes, but the passages do not disclose customer contract provisions governing price resets, renewal terms or pricing restrictions. Competitive pressure alone does not establish contractual freedom.
Predictability100
Five consecutive annual periods. Equal weights: nondeclining revenue frequency; revenue-growth volatility (5–40pp); positive FCF frequency; FCF-margin volatility (3–20pp). Stability indicator, not a growth forecast.
- Nondeclining revenue years (%)
- 100.00
- Revenue growth volatility (pp)
- 2.25
- Positive FCF years (%)
- 100.00
- FCF margin volatility (pp)
- 3.19
Financial strength80
Equal-weight grades: debt/FCF (1–8x), net debt/earnings before interest and tax (0–5x), interest service (1–12x), current ratio (0.75–2x). Earnings use reported operating income, or reported pretax profit plus reported interest expense when operating income is unavailable. Interest service uses earnings/interest expense; if unavailable, it uses reported operating cash flow/cash interest paid, without relabeling cash paid as accrued expense. Nonpositive cash flow/earnings score 0 for their service component; reported zero interest with a positive numerator scores 100. Net cash scores 100 for net leverage. Missing disclosures remain unavailable. General nonfinancial-company rubric, not a credit rating; exceptional and nonoperating gains are not normalized out. IFRS finance-cost and cash-flow classifications retain their reported scope.
- debtFcfGrade
- 57.71
- netDebtEbitGrade
- 60.34
- interestCoverageGrade
- 100.00
- currentRatioGrade
- 100.00
- Debt / FCF (x)
- 3.96
- Net debt / operating income (x)
- 1.98
- Interest coverage (x)
- 14.97
- Current ratio (x)
- 3.03
Capital allocation96
Three-year equal-weight indicators: pretax return on average invested capital (0–25%; equity + debt − cash, each year and its prior year), share-count growth (0–5%, lower better), share-based cost/revenue (2–20%, lower better), consolidated FCF/net income (0–1x). Return uses reported operating income or, if unavailable, EBIT calculated from reported pretax profit plus reported interest expense; exceptional/nonoperating gains are not normalized out. Share-based cost uses the reported cash-flow add-back or, if absent, separately reported recognized compensation expense; the latter never becomes an FCF adjustment. Nonpositive net income scores 0 for cash conversion; absent income/FCF stays unavailable. Nonpositive invested capital has no defined return and remains unavailable. Does not establish acquisition quality or buyback timing.
- 3-year pre-tax operating return (%)
- 32.65
- 3-year average dilution (%)
- -1.84
- 3-year average SBC / revenue (%)
- 0.79
- cashConversionGrade
- 82.66
Management63
Equal-weight average of four evidence-backed rubric grades (0–4), scaled to 100.
capital discipline · 2/4 · Actual shareholder distributions and increased R&D spending show capital deployment. Substantial convertible-note-funded repurchases add financing and potential dilution exposure, while realized divestiture losses and impairments temper the record. The passages do not establish superior investment returns or complete cash-flow coverage.
incentive alignment · 3/4 · Actual 2026 PSU grants have three-year relative TSR and operational revenue growth conditions, while annual incentives include revenue, adjusted EPS and free cash flow. These are implemented alignment mechanisms, not proposed awards or evidence of completed vesting. Aggregate insider ownership below 1% and incomplete payout evidence limit the conclusion.
execution · 2/4 · Completed regulatory approvals, commercial launches and associated demand demonstrate execution. Competitive franchise declines and lower U.S. earnings make the overall record mixed. Commercial execution is assessed partly from indirect product-demand evidence; pipeline expectations and CEO accolades are excluded.
governance · 3/4 · Existing majority voting, documented board refreshment, independent compensation approval, auditor-service pre-approval and an adopted related-person transaction policy provide strong evidence of governance mechanisms. Their existence does not prove exceptional oversight effectiveness or establish the outcome of proposed shareholder resolutions.
Evidence
Our product portfolio enjoys the protection of more than 5,500 granted patents and 1,600 pending patent applications, filed in over 50 countries, with a focus on our major markets, including Australia, Brazil, Canada, China, Europe, Japan and the U.S., as well as other countries with strong patent systems.
Business / Intellectual Property / granted patents and applications · Filed 12/02/2026
In addition, many of our vaccine products and other products are based on or incorporate proprietary information, including proprietary master seeds and proprietary or patented adjuvant formulations.
Risk Factors / proprietary vaccine master seeds and adjuvant formulations · Filed 12/02/2026
We depend on patents and regulatory data exclusivity periods to provide us with exclusive marketing rights for some of our products.
Risk Factors / patent and regulatory data exclusivity · Filed 12/02/2026
•Secured the industry’s first regulatory approvals for long-acting anti-nerve growth factor monoclonal antibody therapies to treat osteoarthritis pain – Lenivia® for dogs and Portela® for cats – in the EU and Canada.
Executive Compensation / CEO 2025 Achievements / completed regulatory approvals · Filed 08/04/2026
•Companion animal operational revenue growth was driven primarily by increased sales of our parasiticides portfolio, as well as an increase in demand for small animal diagnostics and our mAb products for pain with the launch of Lenivia® and Portela™, the company's long-acting monoclonal antibody pain products, partially offset by decreased sales of key dermatology products.
MD&A / second-quarter International companion-animal results and launches · Filed 06/08/2026
In certain circumstances, our products have become subject to decreased sales and we have been forced to lower our prices and provide discounts or rebates in order to compete with generic products.
Risk Factors / realized generic-related sales declines and price concessions · Filed 12/02/2026
The company's key dermatology franchise and Simparica Trio faced heightened competitive pressure and persistent macroeconomic-driven price sensitivity.
MD&A / second-quarter U.S. dermatology and Simparica Trio competitive pressure · Filed 06/08/2026
Also contributing to the decline was the impact of generic competition on Cerenia and Convenia, as well as lower sales of Librela.
MD&A / second-quarter generic competition and lower Librela sales · Filed 06/08/2026
The extent of protection afforded by our patents varies from country to country and is limited by the scope of the claimed subject matter of our patents, the term of the patent and the availability and enforcement of legal remedies in the applicable country and potential legislative or regulatory changes to the underlying patent framework.
Risk Factors / limits on patent protection · Filed 12/02/2026
In addition, in circumstances where Pfizer has an interest in the licensed intellectual property in connection with its human health development programs, our rights to use the licensed intellectual property are restricted and/or, in limited instances, subject to Pfizer's right to terminate such license at will.
Risk Factors / Pfizer license restrictions and termination rights · Filed 12/02/2026
In the animal health field, Pfizer has the first right, and in some cases the sole right, to enforce such licensed patents, and in the human health field, subject to certain exceptions, Pfizer has the sole right to enforce the licensed patents.
Risk Factors / Pfizer rights to enforce licensed patents · Filed 12/02/2026
As a result, we believe that significant brand loyalty to products often continues after the loss of patent-based and regulatory exclusivity.
Business / management belief concerning post-exclusivity brand loyalty · Filed 12/02/2026
Poultry products grew due to increased demand for vaccines, as well as price.
MD&A / first-half U.S. poultry demand and realized pricing · Filed 06/08/2026
six months ended June 30, 2025 Cost of sales as a percentage of revenue was 27.8% in the six months ended June 30, 2026, compared with 27.4% in the six months ended June 30, 2025.
MD&A / first-half consolidated cost of sales as a percentage of revenue · Filed 06/08/2026
The increase was primarily a result of: •unfavorable product mix; and •unfavorable foreign exchange, partially offset by: •favorable manufacturing and other costs; and •price increases.
MD&A / mix, foreign exchange, manufacturing costs and price effects · Filed 06/08/2026
•Companion animal operational revenue growth was driven primarily by increased sales of our parasiticides portfolio, as well as an increase in demand for small animal diagnostics and vaccines, partially offset by decreased sales of key dermatology products.
MD&A / first-half International companion-animal demand by product · Filed 06/08/2026
Growth in the current period was positively impacted by operational changes made in connection with the Fiscal Year Alignment.
MD&A / fiscal-year alignment benefit to International growth · Filed 06/08/2026
U.S. segment earnings decreased by $175 million, or 10%, in the six months ended June 30, 2026, compared with the six months ended June 30, 2025, primarily due to lower gross profit, partially offset by lower operating expenses.
MD&A / first-half U.S. segment earnings decline · Filed 06/08/2026
In connection with the December 18, 2025 private offering of 0.250% convertible senior notes, we purchased approximately 2.1 million shares of Zoetis’ common stock, par value $0.01 per share, for $248 million in privately negotiated transactions entered into concurrently with the pricing of the convertible senior notes offering effected with or through one of the initial purchasers or its affiliate.
Liquidity and Capital Resources / convertible-note-funded initial repurchases · Filed 06/08/2026
Following the date of the offering, we used $1,535 million of the remaining proceeds from the offering for additional repurchases of 12.3 million shares of common stock which repurchases were completed as of March 31, 2026.
Liquidity and Capital Resources / completed additional note-funded repurchases · Filed 06/08/2026
We paid $889 million in dividends and repurchased $3,235 million in Zoetis common stock under our share repurchase program.
Executive Compensation / actual 2025 dividends and repurchases · Filed 08/04/2026
For 2024, certain significant items primarily consisted of employee termination costs related to organizational structure refinements, a net loss related to the sale of our medicated feed additive product portfolio, certain water soluble products and related assets, as well as asset impairment charges related to our aquaculture business, partially offset by a reversal of certain employee termination costs as a result of a change in strategy from our 2015 operational efficiency initiative.
Segment reporting / realized divestiture loss and aquaculture impairment · Filed 12/02/2026
During the six months ended June 30, 2026, the company granted 183,488 PSUs with a weighted-average grant date fair value of $156.44 per PSU.
Note 12 / actual first-half 2026 PSU grants · Filed 06/08/2026
Beginning in 2025, the units underlying the PSUs will be earned and vested over a three-year performance period in two tranches, each subject to an independent achievement condition: (1) a market condition comprising the total shareholder return of the company in comparison to the total shareholder return of the companies comprising the S&P 500 Health Care index at the start of the performance period, excluding companies that during the performance period are acquired or no longer publicly traded (Relative TSR); and (2) a performance condition comprising a three-year average annual operational revenue growth metric (average PSU operational revenue growth).
Note 12 / three-year relative TSR and operational revenue growth vesting conditions · Filed 06/08/2026
•The AIP pool is funded based on Zoetis’ performance against revenue, adjusted diluted EPS and free cash flow goals.
Executive Compensation / annual incentive financial metrics · Filed 08/04/2026
(7)The directors and executive officers as a group do not own more than 1% of the total outstanding shares based on 420,640,004 shares outstanding on March 20, 2026.
Ownership / directors' and executive officers' aggregate ownership limitation · Filed 08/04/2026
Director since December 2025 Board Refreshment 4 New independent directors have been added to the Board in the last four years Zoetis 2026 Proxy Statement 7 Corporate Governance at Zoetis Majority Voting Standard for Director Elections Our Amended and Restated By-laws (the “By-laws”) contain a majority voting standard for all uncontested director elections.
Corporate Governance / board refreshment and existing majority voting standard · Filed 08/04/2026
The Human Resources Committee, with the advice of its independent compensation consultant, approves the compensation for the NEOs (other than the CEO) and the other members of the ZET, and recommends the compensation of the CEO to our full Board for approval by its independent members.
Executive Compensation / independent approval of CEO compensation · Filed 08/04/2026
Prior to engagement, the Audit Committee pre-approves independent registered public accounting firm services within each category, and the fees for each category are budgeted.
Audit Committee / auditor-service pre-approval · Filed 08/04/2026
Zoetis 2026 Proxy Statement 93 Transactions with Related Persons Policy Concerning Related Person Transactions Our Board has adopted a written policy regarding the review and approval of transactions with related persons.
Transactions with Related Persons / adopted written review policy · Filed 08/04/2026
Patents for individual products expire at different times based on the date of the patent filing (or sometimes the date of patent grant) and the legal term of patents in the countries where such patents are obtained.
Business / differing product patent expiration dates · Filed 12/02/2026
R&D expenses increased by $18 million, or 11%, in the three months ended March 31, 2026, compared with the three months ended March 31, 2025, primarily as a result of:
MD&A / actual first-quarter 2026 R&D spending increase · Filed 07/05/2026
